Related Experiment Videos
Pharmacokinetics of roxithromycin in paediatrics
P Bégué1, D A Kafetzis, H Albin
1Trousseau Hospital, Paris, France.
The Journal of Antimicrobial Chemotherapy
|November 1, 1987
Summary
Roxithromycin, a macrolide antibiotic, shows similar pharmacokinetics in children and adults. A dose of 2.5 mg/kg every 12 hours is suggested for pediatric use, with good tissue penetration in the respiratory tract.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Infectious Diseases
Background:
- Macrolides are recognized for high lipid solubility and tissue penetration.
- Roxithromycin is a novel semisynthetic macrolide antibiotic.
- Initial pharmacokinetic data in adults suggest favorable properties.
Purpose of the Study:
- To evaluate the pharmacokinetic profile of roxithromycin in pediatric patients.
- To compare pediatric pharmacokinetics with existing adult data.
- To determine an appropriate dosing regimen for children.
Main Methods:
- Summary of five pediatric pharmacokinetic studies.
- Analysis of roxithromycin absorption, distribution, metabolism, and excretion in children.
- Comparison of pediatric data with adult pharmacokinetic parameters.
Main Results:
- Pediatric pharmacokinetic properties of roxithromycin are comparable to those in adults.
- Roxithromycin demonstrates good diffusion into pediatric upper respiratory tract tissues.
- The established adult dosing regimen appears suitable for pediatric patients.
Conclusions:
- Roxithromycin exhibits similar pharmacokinetic behavior in pediatric and adult populations.
- A dosage of 2.5 mg/kg administered every 12 hours is recommended for pediatric use.
- Roxithromycin's favorable tissue penetration supports its use in pediatric respiratory tract infections.